Halozyme TherapeuticsvsMerck & Company

HALO and MRK stock compared: price, dividend, valuation and results, from SEC filings.

HALO

Halozyme Therapeutics, Inc.

$93.03

Value $11.0B

-0.01%
HALO's page

MRK

Merck & Company, Inc.

$134.62

Value $333B

+1.36%
MRK's page

Halozyme Therapeutics (HALO) has a market value of $11.0B and Merck & Company (MRK) $333B. Over the last year, with dividends, HALO moved +32.4% and MRK +45.8%. The P/E is 22.6 for HALO and 135.7 for MRK. Dividend yield: HALO none, MRK 2.53%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    HALO$11.0B

    MRK$333B

    MRK is 30 times HALO

  • Revenue, 12 months

    HALO$1.8B

    MRK$67.4B

    MRK is 37 times HALO

  • Net income, 12 months

    HALO$485M

    MRK$2.5B

    MRK is 5.1 times HALO

  • Operating margin

    HALO37.4%

    MRK–

  • ROIC

    HALO20.7%

    MRK3.9%

    16.8 points apart

  • P/E

    HALO22.6

    MRK135.7

    MRK is 6.0 times HALO

  • Dividend yield

    HALO0.0%

    MRK2.5%

    2.5 points apart

  • 5-year return

    HALO+161.9%

    MRK+94.3%

    67.6 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

HALO+161.9%

MRK+94.3%

10020030020222023202420252026
Returns by period
PeriodHALOWith dividendsMRKWith dividends
1 year since November 19, 2025+32.4%Price +32.4%+45.8%Price +41.6%
3 years since November 20, 2023+132.5%+32.5% a yearPrice +132.5%+43.7%+12.8% a yearPrice +31.1%
5 years since November 19, 2021+161.9%+21.2% a yearPrice +161.9%+94.3%+14.2% a yearPrice +66.8%
10 years since November 21, 2016+636.1%+22.1% a yearPrice +636.1%+207.2%+11.9% a yearPrice +126.4%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

HALOHalozyme TherapeuticsMRKMerck & Company

Valuation

HALOMRK
Valuation
Price$93.03$134.62
Market value$11.0B$333B
Enterprise value (EV)$13.2B$377B
P/E22.6135.7
P/E, 5-year median17.614.8
P/B–7.4
EV/EBIT19.579.2
Free cash flow yield8.1%4.4%

Results and growth

HALOMRK
Results and growth
Revenue, 12 months$1.8B$67.4B
Net income, 12 months$485M$2.5B
Free cash flow, 12 months$886M$14.7B
Earnings per share, 12 months$4.01$0.98
Revenue growth, year on year37.6%1.3%
Revenue growth a year, past+39.2%over 5 years+9.4%over 5 years
EPS growth a year, past+23.0%over 5 years+21.2%over 5 years

Margins and returns on capital

HALOMRK
Margins and returns on capital
Gross margin82.3%71.8%
Operating margin37.4%–
Net margin26.9%3.6%
ROIC20.7%3.9%
ROE282.0%5.2%

Balance sheet

HALOMRK
Balance sheet
Cash$1.1B$9.7B
Total debt$3.3B$53.8B
Net debt / EBITDA3.25.7
Interest cover30.6×2.4×

Dividends and buybacks

HALOMRK
Dividends and buybacks
Dividend yield–2.5%
Dividend per share, 12 months–$3.40
Dividend growth a year, past–+5.8%over 5 years
Buyback yield3.1%1.5%
Shareholder yield3.1%4.1%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: HALO or MRK

Didn't find what you were looking for?

Ask us
Which is bigger, Halozyme Therapeutics or Merck & Company?

By market value, Merck & Company ($333B) is about 30.3 times Halozyme Therapeutics ($11.0B), at today's prices.

How did HALO and MRK stock do over the last 10 years?

Since November 21, 2016, HALO's price moved +636.1% and MRK's +126.4%. With dividends: HALO +636.1% (+22.1% a year), MRK +207.2% (+11.9% a year). Past returns do not predict future ones.

Which pays the higher dividend, HALO or MRK?

The dividend yield at today's price is none for Halozyme Therapeutics and 2.53% for Merck & Company. Over the last twelve months they paid – and $3.40 per share.

What is the P/E of HALO and MRK?

At today's price, the P/E is 22.6 for HALO and 135.7 for MRK. The median of the last five years was 17.6 and 14.8, which shows where each stands against its own past.

Which has the higher profit margins, Halozyme Therapeutics or Merck & Company?

Over the last twelve months, the net margin was 26.9% for Halozyme Therapeutics and 3.6% for Merck & Company, and the operating margin 37.4% and –. Revenue was $1.8B and $67.4B.

Which is the better investment, Halozyme Therapeutics or Merck & Company?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.